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ABSTRACT 
We designed and synthesized perhexiline analogues that have the same therapeutic profile 
as the parent cardiovascular drug, but lacking its metabolic liability associated with CYP2D6 
metabolism. Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further 
development as they retained a pharmacokinetic profile very similar to that shown by the 
parent compound. Multi-step synthesis of perhexiline analogues incorporating fluorine atoms 
onto the cyclohexyl ring(s) provided a range of different fluoro-perhexiline analogues. Of 
these, analogues 50 (4,4-gem-difluoro) and 62 (4,4,4’,4’-tetrafluoro) were highly stable and 
showed greatly-reduced susceptibility to CYP2D6-mediated metabolism. In vitro efficacy 
studies demonstrated that a number of derivatives retained acceptable potency against 
CPT-1. Having the best balance of properties, 50 was selected for further evaluation. Like 
perhexiline, it was shown to be selectively concentrated in the myocardium and, using the 
Langendorff model, to be effective in improving both cardiac contractility and relaxation when 
challenged with high fat buffer.  
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INTRODUCTION 
The therapeutic potential of perhexiline 1 (PHX, Fig. 1) in the treatment of cardiovascular 
disorders has been known for almost 50 years1,2 and the drug was introduced in 1973 for the 
treatment of angina,3 for which it has considerable efficacy and indeed continues to be used 
in some centres for patients with refractory angina. Perhexiline shifts myocardial metabolism 
from fatty acid to carbohydrate utilisation, thereby increasing metabolic efficiency (i.e. it 
produces relatively more ATP for a given oxygen consumption). By increasing myocardial 
efficiency, perhexiline has the potential to treat a range of disorders in which impaired 
cardiac energetics or oxygen deficiency play a role. In addition to angina, perhexiline has 
been investigated and used off-label for the treatment of heart failure, giving unprecedented 
improvements in VO2 max, quality of life improvement and left-ventricular ejection fraction;4 for 
acute coronary syndromes;5 inoperable aortic stenosis6 and hypertrophic cardiomyopathy.7 
The latter study has led the FDA to award orphan drug status to perhexiline. Furthermore, by 
its inhibitory action on fatty acid β-oxidation, it has been hypothesised that perhexiline may 
have potential in anti-neoplastic therapies to target tumour metabolism, either alone or in 
combination with existing therapeutic regimens (e.g., to increase susceptibility to 
chemotherapy).8,9 
 
 
 
Figure 1. Perhexiline 1 and its enantiomers.10 
 
However, perhexiline was removed from most markets by 1988, due to side-effects including 
hepatotoxicity and neurotoxicity.11 The side-effects leading to withdrawal of the drug were 
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due to sustained high plasma levels of the drug, in a small subgroup of patients, as a result 
of variable (apparently unpredictable) metabolism. This led to phospholipid accumulation in 
the liver and peripheral nerves, due to complete blockade of mitochondrial long chain fatty 
acid uptake. Metabolism of perhexiline, hydroxylation at the 4-positions of either of the 
cyclohexyl rings, is mediated primarily by CYP2D6. CYP2D6 is polymorphic, giving 
substantial inter-individual variation in the rate of metabolism of drugs upon which it acts. An 
approximate 100-fold range is seen in the rate of perhexiline clearance and the required 
dosage ranges from 100 mg/week to 500 mg/day.12 These issues can be avoided with close 
patient monitoring,11 but such monitoring is not practical outside well-controlled patient 
groups, and thus it is unlikely that perhexiline can ever again be used in a wider patient 
population. Recent studies investigating the potential of using pure enantiomers 1a,b (Fig. 1) 
of perhexiline have suggested differences in myocardial uptake, clearance, route of 
metabolism and, potentially, activity and toxicity; however, it is not yet clear as to whether 
these data will translate to therapeutic relevance.13,14,15 
Perhexiline has been described as a drug of “low potency, low specificity, and low selectivity” 
and as having actions on a diverse range of molecular targets, some of which remain to be 
properly defined, which contribute to its therapeutic benefit in heart failure (HF).16  However, 
at present, the therapeutic action of perhexiline is generally still thought to be due to 
inhibition of CPT-1 and to a lesser extent CPT-2.11,17 CPT is an enzyme responsible for 
mediating mitochondrial uptake of long chain fatty acids, by coupling them to carnitine; the 
acylated carnitine is then taken into the cell by a carnitine acyl-carnitine translocase. 
Preventing free fatty acid transport across mitochondrial cell membranes causes a 
corresponding shift to greater carbohydrate usage and an increase in myocardial efficiency 
(10 - 40%; more in some studies,11 in terms of ATP generated per unit of oxygen). This 
oxygen-sparing effect is of particular significance in the treatment of angina and heart failure, 
allowing cardiac output to remain constant in spite of reduced cardiac oxygen extraction. 
Perhexiline inhibits CPT-1 with modest potency (IC50 = 77 µM and 148 µM in rat cardiac and 
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liver mitochondria) and inhibits CPT-2 (79 µM) and fatty acid oxidation (β-oxidation) in 
hepatocytes at 22 µM, resulting in increased lactate and glucose utilisation.18 Whilst the 
effective contribution of CPT inhibition has also been questioned,15,16,18 a further argument in 
support of the importance of CPT-1 inhibition as the mechanism of action, in spite of the 
apparent lack of potency, is the tendency for perhexiline to become concentrated in tissues, 
including the myocardium.18 Thus the concentration in the vicinity of mitochondrial CPT-1 is 
thought to exceed the modest IC50. This characteristic is attributed to its amphipathic 
nature,11 though this has also been highlighted as the source of the proposed diverse 
actions of perhexiline16 and may also complicate attempts to determine the role of 
stereoselectivity in the therapeutic activity of perhexiline. 
 
In spite of the therapeutic potential and the well-understood toxicity issues, which led to its 
removal from clinical usage throughout most of the world, few attempts have been made to 
modify the chemical structure of perhexiline. To date, only a small number of reports on 
derivatives have been published19,20 and derivatives with improved properties (relative to 
perhexiline) have not been reported. It is clear that compounds which have the same 
therapeutic profile as perhexiline, but which lack the metabolic liability associated with 
CYP2D6 metabolism, could be highly effective therapeutic agents for the treatment of a 
range of cardiovascular conditions.  In the absence of complex and variable 
pharmacokinetics, such a compound would not be restricted to limited patient populations or 
to use in a clinical environment, and thus could benefit a wider patient population for a range 
of cardiovascular diseases. In this report we describe the successful blocking of CYP2D6-
mediated metabolism by addition of fluorine atoms at the sites of metabolism and 
demonstrate that these compounds have broadly equivalent potency to that of perhexiline 
against CPT-1. 
 
RESULTS AND DISCUSSION 
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Chemistry and in vitro pharmacokinetics. In the absence of satisfactory hypotheses 
concerning how perhexiline exerts its therapeutic and toxicological actions, there is no clear 
guidance as to how the properties could be optimised. For example, there is no evidence 
that a more potent CPT-1 inhibitor would necessarily be preferred. Thus, our primary aim for 
this programme was to develop compounds having the same activity profile as perhexiline, 
but lacking the CYP2D6 liability. The obvious route to achieve this was the development of 
compounds which were structurally as similar to perhexiline as possible, in the hope that the 
therapeutic effects could be decoupled from the metabolic liability. There have been 
surprisingly few attempts made previously to generate even simple perhexiline analogues.  
These have included N-substituted derivatives,20 derivatives in which the piperidine has 
been replaced by other amine-bearing groups,19 derivatives in which the carbon separating 
the two cyclohexyl groups has been substituted with a carbinol group21 and the synthesis of 
a deuterated derivative has also been described.22 
As perhexiline can be hydroxylated on either cyclohexyl ring by CYP2D6, our initial focus 
was on the synthesis of analogues in which one or both of the cyclohexyl rings had been 
replaced by cycloalkyl rings of similar size (Scheme 1).  
-Valerolactone was treated with methyl lithium and the resulting 6-hydroxy-hexan-2-one 
was transformed into the corresponding TBS-ether. The latter was treated with LDA and 
subjected to aldol reaction with aldehydes affording the -hydroxy-ketones 2a-d. The 
crotonic adducts 3a-d were obtained by DBU-promoted -hydroxy elimination of the 
intermediate mesylates. Introduction of the second group of the perhexiline-like structure 
was achieved by Michael reaction upon treatment of 3 with the corresponding cuprates,23 
then the intermediate silyl enol ethers 4 were deprotected and the primary carbinol group 
was oxidized with Dess-Martin periodinane (DMP) to provide the aldehydes 5a-h (62 – 81% 
yields). The latter were subjected to reductive amination/cyclization24 affording the small 
library of perhexiline analogues 6a-h, which were isolated as mixtures of stereoisomers in 
good to excellent yields (78 – 91%). 
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Scheme 1.Synthesis of cycloalkyl perhexiline analogues 6a-h. Reagents and conditions: (a) 
MeLi, -78 °C, then TBSCl and imidazole (93%); (b) LDA, -78 °C, then R2CHO; (c) MsCl, TEA 
then DBU; (d) RM (M = Mg or Li), Cu(I)X (see experimental section), TMSCl, -78 °C; (e) 
PTSA, MeOH- CH2Cl2; (f) DMP (62-81% over steps d-f); (g) NH4OAc, NaBH3CN, MeOH (78-
91%). 
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The THP analogue 6i and the gem-dimethylcyclohexyl analogue 6j (Fig. 2) were prepared 
following different synthetic routes (see Supporting Information for details).  
 
 
Figure 2. 
 
Disappointingly, in human and rat liver microsomal (HLM / RLM) stability studies, 
compounds 6a-j all retained a stability profile very similar to that shown by the parent 
compound. We therefore turned our attention to the addition of fluorine atoms onto the 
cyclohexyl ring, as another potential route towards either physically blocking the site of 
metabolism, or to deactivating the ring towards oxidation by reduction of electron density.25 
 
With the view of introducing fluorine by dehydroxyfluorination, we first synthesised 4-
hydroxy-perhexiline 24 (Scheme 2) from ethyl 4-hydroxycyclohexane-carboxylate. 
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Scheme 2. Synthesis of 4-hydroxy-perhexiline 24. Reagents and conditions: (a) MOMCl, 
DIPEA, CH2Cl2 (93%); (b) Aq. NaOH, then NaBH4, THF, H2O, then Swern oxidation (87% 
over three steps); (c) Cyclohexyl magnesium bromide, Et2O (91%); (d) Py2Cr2O7, CH2Cl2 
(83%); (e) nBuLi, 2-picoline then SOCl2; (f) PtO2, H2 (1 atm), MeOH; (g) TFA, CH2Cl2 then 
NaOH (82% over steps e-g). 
 
The synthesis of fluorinated perhexiline derivatives proved unexpectedly difficult and the 
standard late-stage fluorination approaches were not successful in introducing a fluorine 
onto position 4 of the cyclohexyl ring. In fact, nucleophilic attack on a 4-cyclohexyl mesylate 
or triflate derived from dicyclohexyl-carbinol 14 (see Supporting Information, Scheme S2) 
using TBAF or KF led to elimination rather than substitution, while use of DAST to effect the 
dehydroxyfluorination of 24 (Scheme 2) – also in N-protected form - led to dehydration. An 
alternative approach, hydrogenation of the potential 4-fluorophenyl precursor 6h (Scheme 1) 
using a number of different catalysts led predominantly to concomitant reductive 
defluorination and gave perhexiline as the end product. Attempts to access vinyl-fluoride 27a 
(See Scheme S3, Supporting Information) via Ag-mediated ipso-fluorodestannylation of the 
corresponding vinyl stannane with electrophilic fluorinating agents resulted in impractical 
outcomes.26 Eventually, we were able to develop multi-step synthetic strategies capable of 
producing enough pure fluoro-perhexilines 31, 42, 50, 55 and 62 (Fig. 3) for performing 
biological tests.  
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Figure 3. Fluoro perhexiline derivatives synthesised in this work. 
 
As an example, the synthesis of 4,4-difluoro-perhexiline 50 (FPER-1) is shown in Scheme 3 
(for detailed information on the synthesis of all fluoro-perhexilines see the Supporting 
Information). Commercially available ethyl 4-hydroxycyclohexane-carboxylate was first 
oxidized to ketone 43 and then submitted to deoxofluorination with DAST, affording an 
inseparable mixture of the desired gem-difluoro-ester 44a and vinyl-fluoride by-product, 
which – for ease of separation - was oxidized with mCPBA to give the fluoro-oxirane 44b. 
This mixture was then reduced with LiAlH4, then FC purification afforded the difluoro-alcohol 
45, which was transformed into the target gem-difluorinated molecule 50 in 5 steps. 
 
 
 
Scheme 3. Synthesis of 4,4-difluoro-perhexiline 50 (FPER-1). Reagents and conditions: (a) 
PCC (88%); (b) DAST; (c) mCPBA; (d) LiAlH4 (62% over steps b-d); (e) Swern oxidation 
(64%); (f) Cyclohexyl magnesium chloride; (g) DMP (86% over steps f-g); (h) nBuLi, 2-
picoline then SOCl2 (88%); (i) Pd(OH)2/C, H2 (1 atm), AcOH, 50 °C (94%). 
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Racemic perhexiline 1 shows reasonable stability in the HLM assay, with a half-life of 100 
minutes, but with a short half-life in RLM of just 21 minutes (Table 1). The relevance of this 
was validated in the presence of CYP2D6-expressing BactosomesTM, in which perhexiline 
was very rapidly turned over, with a half-life of just 14 minutes. As these rat liver microsomes 
are prepared from Sprague-Dawley rats, regarded as a model for CYP2D6 extensive 
metabolisers,12 this is a logical correlation.  The closest analogue of perhexiline 6c, in which 
one cyclohexyl had been replaced by a cyclopentyl ring, showed near identical stability to 
the parent compound in both the RLM and CYP2D6 assays. As shown in Table 1, none of 
these unsubstituted cycloalkyl analogues 6a-j showed significantly improved RLM stability 
compared to perhexiline 1. The improved stability of “(+)-perhexiline” (absolute 
stereochemistry not defined at that stage) has previously been proposed.27 The results 
shown in Table 1 may be taken to suggest that (R)-(+)-perhexiline 1a was more stable than 
(S)-(-)-perhexiline 1b in the HLM assay (98 and 65 min, respectively), whilst the two 
enantiomers had the same stability in the RLM assay (10 and 11 min, respectively). 
However, in view of the apparent lower stability of both of the two enantiomers in 
comparison with the racemic parent compound 1 in the RLM assay (21 min; a highly 
unlikely, if not impossible occurrence) we do not feel that this assay can be used to draw any 
conclusions concerning relatively small differences in potency. However, we were able to 
conclude that replacement of one or both cyclohexyl groups with other cycloalkyl groups did 
not remove the CYP2D6 liability. Other modifications, including the addition of a gem-
dimethyl onto one of the cyclohexyl rings (6j), or replacement of one of the rings with a 4-
tetrahydropyranyl (6i), with a phenyl (6g), or with a 4-fluorophenyl (6h), did not lead to 
significant improvements in the PK profile. The 4-tetrahydropyran derivative 6i gave an 
apparent gain in RLM stability, but this was not reflected by any improvement in stability to 
CYP2D6.  These results suggested that it would be necessary to either replace both 
cyclohexyl rings, or to more strongly deactivate a remaining cyclohexyl ring in order to 
remove the metabolic liability.  Disappointingly, and unexpectedly, the addition of one 
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fluorine (compound 31) gave no improvement in stability and, equally surprisingly, the 
addition of one fluorine on each cyclohexyl (compound 42) gave a compound which was 
chemically unstable on storage in pure form. All other compounds showed no decomposition 
on incubation for 1 h in pH 7.4 PBS at 37 °C. It is not clear as to what caused this instability, 
but this compound was not further evaluated.  At the other end of the scale, as predicted, the 
tetrafluoro derivative 62, in which all of the potential sites for metabolism, as identified by 
previous studies28 had been blocked, was extremely stable. Perhaps most interestingly, the 
addition of a 4,4-difluoro group onto just one of the cyclohexyl rings (compound 50) also 
gave a very substantial increase in stability over the parent compound, and stability in the 
HLM, RLM and CYP2D6 assays had increased to >500, 72 and 104 min respectively (Table 
1). Our hypothesis, aimed at leaving as much of the parent structure intact as possible, was 
that one, but perhaps not both, of the cyclohexyl rings formed an essential binding 
interaction with the target. Thus a derivative might be more likely to retain activity if only one 
ring had been modified.  With this in mind, we also prepared the 3,3-difluorocyclohexyl 
derivative 55, feeling that the reduction in electron density from a more distant group could 
be sufficient to reduce metabolism, whilst at the same time perhaps interfering less with a 
binding interaction. However, this compound did not show the same improvement in stability. 
These data show that certain fluorinated perhexiline analogues are much less heavily 
metabolised by CYP2D6 than perhexiline and thus should avoid the inter-individual 
variability which compromises perhexiline therapy. Therefore, these compounds are 
expected to show more reliable and predictable pharmacokinetics and hence may also avoid 
the toxicity issues found with perhexiline.   
 
Table 1. Human and rat liver microsomal (HLM / RLM) stability studies. 
 
 R1 R2 
HLM 
t1/2 (min)  
RLM 
t1/2 (min)  
CYP2D6 
t1/2 (min) 
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± SEM ± SEM ± SEM 
(±)-PHX 1 Cyclohexyl Cyclohexyl 100 ± 1 21 ± 1 14 ± 3 
(+)-(R)-PHX 1a Cyclohexyl Cyclohexyl 98 ± 25 10 ± 0.8 - 
()-(S)-PHX 1b Cyclohexyl Cyclohexyl 65 ± 9 11 ± 0.4 - 
6a Cyclohexyl Cyclopropyl 124 ± 18  3 ± 0.5 - 
6b Cyclohexyl Cyclobutyl >200 10 ± 0.6 - 
6c Cyclohexyl Cyclopentyl >150 19 ± 2 16 ± 1 
6d Cyclopentyl Cyclopropyl 27 ± 2 3 ± 0.04 - 
6e Cyclopentyl Cyclobutyl 51 ± 5 7 ± 0.5 - 
6f Cyclopentyl Cyclopentyl 50 ± 4 14 ± 1 - 
6g Cyclohexyl Phenyl 56 ± 7 4 ± 0.3 - 
6h Cyclohexyl 4-Fluorophenyl 79 ± 8 7 ± 0.2 - 
6i Cyclohexyl 
4-Tetrahydro 
pyranyl 
84 ± 21 31 ± 1 7 ± 0.8 
6j Cyclohexyl 
4,4-Dimethyl 
cyclohexyl 
77 ± 11 20 ± 1 - 
31 Cyclohexyl 4-Fluoro cyclohexyl 65 ± 7 11 ± 0.9 16 ± 0.5 
50 Cyclohexyl 
4,4-Difluoro 
cyclohexyl 
>500  72 ± 6 104 ± 17 
55 Cyclohexyl 
3,3-Difluoro 
cyclohexyl 
>150 35 ± 1 - 
42 
4-Fluoro 
cyclohexyl 
4-Fluoro cyclohexyl - - - 
62 
4,4-Difluoro 
cyclohexyl 
4,4-Difluoro 
cyclohexyl 
>4000 >1500  >150 
 
Biology:  We compared our compounds to perhexiline 1 in a suitable efficacy model in 
which perhexiline has shown potency. Compound selection was guided by first determining 
in vitro inhibitory potency against the most widely accepted target for perhexiline, CPT-1 
(Table 2).  Inhibitory potency against rat mitochondrial CPT-1 in vitro was measured by 
determining the ability of derivatives to inhibit the conversion of palmitoyl CoA and L-
carnitine into palmitoylcarnitine, measuring the disappearance of palmitoyl CoA 
spectrophotometrically, as described previously.29 In this assay the ~50% of the CPT activity 
that is sensitive to inhibition by malonyl CoA is defined as CPT-1,29 and under the conditions 
of the assay we obtained an IC50 of 1.2 µM for malonyl CoA. Since all tested inhibitors also 
showed the same maximal inhibition of activity as malonyl CoA, we assumed that this also 
represents inhibition of CPT-1.  
We found that the gem-difluoro derivative 50 showed only a small loss in inhibitory potency 
(45 µM, P<0.05) compared to racemic perhexiline 1 (11 µM) and its (S) enantiomer 1b (14 
µM). The apparent increased potency of the (S) enantiomer 1b matches the published 
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suggestion that “()-perhexiline” might have better therapeutic properties.14 The (R) 
enantiomer 1a shows a significant reduction in potency compared to racemic perhexiline 1 
(32 µM, P<0.05) and approaches significance when compared to the (S) enantiomer 1b. 
This compares to a literature value of 77 µM for perhexiline 1.17 However, the difficulties in 
obtaining precise and consistent data for CPT-1 inhibition have been noted and discussed 
by Ceccarelli.18  The exceptionally stable tetrafluoro derivative 62 had lost some of its activity 
against CPT-1 (88 µM, P<0.05 compared to 50). Replacement of one cyclohexyl with a 
cyclopentyl in compound 6c had no impact on potency (11 µM), whilst replacement of both 
cyclohexyls with cyclopentyl groups, in compound 6f, gave a non-significant reduction in 
potency (19 µM). However, the hypothesis that retaining one intact cyclohexyl might be 
sufficient to retain activity, whilst a wide range of modifications on the other might be 
tolerated, was disproved by the loss of potency seen with the 3,3-difluoro 55 (215 µM) and 
tetrahydropyran 6i (715 µM) derivatives.  We also investigated the stereoisomeric mixture of 
4-hydroxy derivatives 24 to study the possibility that the activity of perhexiline was in-part 
mediated through a metabolite,28 but instead found it to be very poorly active (475 µM).  
Having the best balance of pharmacokinetic and inhibitory properties, plus relative ease of 
synthesis, we selected the 4,4-gem-difluoro 50 derivative to take forward for in vivo PK and 
efficacy study. 
 
Table 2. CPT-1 inhibitory activities. 
 
R1 R2 
IC50 for CPT-1 
inhibition (µM)* 
(±)-PHX 1 Cyclohexyl Cyclohexyl  11 (7 - 17) 
(+)-(R)-PHX 1a Cyclohexyl Cyclohexyl  32 (24 - 41) 
()-(S)-PHX 1b Cyclohexyl Cyclohexyl  14 (8 - 25) 
6c Cyclohexyl Cyclopentyl 11 (5 - 24) 
6f Cyclopentyl Cyclopentyl 19 (7 - 40) 
6i Cyclohexyl 4-Tetrahydropyranyl 715 (510 - 1050) 
50 Cyclohexyl 4,4-Difluorocyclohexyl 45 (34 - 60) 
55 Cyclohexyl 3,3-Difluorocyclohexyl 215 (160 - 290) 
62 4,4-Difluorocyclohexyl 4,4-Difluorocyclohexyl 88 (61 - 127) 
24 Cyclohexyl 4-Hydroxycyclohexyl 475 (290 - 745) 
* mean and pooled 95% confidence interval of two independent experiments. 
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In vivo pharmacokinetics: It has been proposed that the unexplained activity of perhexiline 
1, in spite of modest in vitro potency against all proposed targets, is due to selective 
accumulation in the myocardium. Thus, in a continued attempt to ensure that our 
compounds mirrored perhexiline in as many aspects as possible, we conducted studies to 
determine the in vivo stability and myocardial exposure.  The distribution and stability of 50, 
following daily oral dosing, were compared to perhexiline in male BALB/c mice (samples 
taken at 1, 4, 8 and 24 h following dosing; n = 3 per timepoint – see supplementary 
information for full details).  Plasma and myocardial concentrations, and area under the 
curve, following 10 mg/kg oral gavage of 50 and perhexiline were investigated. In the mouse 
model, perhexiline 1 is very rapidly metabolised and thus no direct comparisons can be 
drawn between the absolute concentrations of the two compounds.  However, Table 3 
shows that there is a significant accumulation of perhexiline in the myocardium (5.7-fold at 1 
h, 4.9-fold at 4 h and 4.8-fold at 8 h, as defined by drug concentration; 2.4-fold as defined by 
AUC), whilst 50 shows an even larger selective accumulation (10.7-fold at 1 h, 10.9-fold at 4 
h and 9.5-fold at 8 h, as defined by drug concentration; 8.6-fold as defined by AUC).   
 
Table 3. In vivo pharmacokinetics in a mouse model 
  
50 
(10 mg/kg) 
Perhexiline 
(10 mg/kg) 
  Plasma Myocardium Plasma Myocardium 
Conc 
(ng/mL) 
1 h 346.5 ± 257.4 3726.8 ± 2808.5 116.4 ± 39.2 664.5 ± 157.5#  
4 h 171.9 ± 44.1* 1877.3 ± 606.1*# 28.3 ± 8.8  125.8 ± 62.5 
8 h 191.8 ± 48.0* 1826.7 ± 498.7*# 6.0 ± 5.6 29.2 ± 25.2 
AUC 0-24 
(hr*ng/mL) 
3763 ± 1501* 32360 ± 7030**## 876 ± 123 2114 ± 265## 
*P<0.05 relative to perhexiline; **P<0.005 relative to perhexiline; #P<0.05 relative to plasma; 
##P<0.005 relative to plasma (Student’s t-test). 
 
Further studies were conducted, showing that selective myocardial accumulation was also 
seen in male Sprague-Dawley rats (used as a model for CYP2D6-mediated metabolism)12 
(Table 4). The distribution and stability of 50 following daily oral dosing were compared to 
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perhexiline 1 (plasma samples taken at 1, 2, 4, 8 and 24 h following dosing; n = 3 per 
timepoint – see Supporting Information for full details).  Again perhexiline is metabolised very 
quickly, which is not representative of the situation in humans, but similar myocardium : 
plasma ratios can be seen in comparing perhexiline 1 (19-fold at 1 h and 11.5-fold at 8 h, as 
defined by drug concentration) and 50 (15.3-fold at 1 h and 7.2-fold at 8 h, as defined by 
drug concentration). 
 
Table 4. In vivo pharmacokinetics in a rat model 
  
50 
(10 mg/kg) 
Perhexiline 
(10 mg/kg) 
  Plasma Myocardium Plasma Myocardium 
Conc 
(ng/mL) 
1 h 386.3 ± 28.4* 5913.4 ± 1350.2# 99.9 ± 43.5 1901.2 ± 887.1#  
2 h 375.4 ± 139.7* - 112.9 ± 32.6  - 
4 h 297.1 ± 145.2 - 97.44 ± 24.3 - 
8 h 178.6 ± 93.4 1285.9 ± 822.8 31.4 ± 5.7 361.2 ± 104.7# 
*P<0.05 relative to perhexiline; #P<0.05 relative to plasma (Student’s t-test) 
 
Thus, assuming that this accumulation is responsible for the therapeutic effect, rather than 
presenting a toxicological liability, 50 appears to match our requirements as an optimised (in 
terms of CYP2D6 liability) orally-bioavailable analogue of perhexiline, suitable for efficacy 
studies.   
 
Ex vivo efficacy studies: The ex vivo Langendorff murine model was used to assess the 
effects of perhexiline 1 and analogue 50 on indicators of cardiac contractility (LVdP/dt max) 
and relaxation (LVdP/dt min) following perfusion with a high fat buffer. In recent years it has 
been shown that HF can be characterised by severe metabolic disturbances, intrinsic to the 
myocardium, which include fatty acid overload and build-up within the cardiomyocyte cytosol 
and mitochondria.30 As such, energy production within the cardiomyocyte is impaired, which 
in turn disrupts cardiac function and contractile activity over time. By perfusing hearts with a 
high fat buffer, we can simulate the fatty acid overload observed during HF and can measure 
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the effects of perhexiline 1 and compound 50 on cardiac function, such as LVdP/dt max and 
min, under these conditions.31 
 
 
Figure 2. Perhexiline 1 and 4,4-gem-difluoro-perhexiline 50 improve cardiac contractility and 
relaxation in a high fat perfusate.  A: The Langendorff perfusion protocol. Hearts were 
stabilised for 10 minutes with BSA-Palmitate and then perfused for 30 minutes with either 1) 
Control (BSA-Palmitate), 2) 2 μM perhexiline, 3) 2 μM 50 or 4) 10 μM 50. Cardiac 
contractility (LVdP/dt max) and cardiac relaxation (LVdP/dt min) were calculated from the left 
ventricular pressure. B: LVdP/dt max. C: LVdP/dt min. Data are presented as mean ± SEM; 
n = 12-19 mice. **P<0.01 vs Control (BSA-Palmitate); ***P<0.001 vs Control (BSA-palmitate) 
(1-way ANOVA, post-hoc Bonferroni test. 
 
The results demonstrate that 2 µM perhexiline 1 shows a strong trend for enhancing LVdP/dt 
max (2.1 fold increase when compared to the control; n=16; P=0.07) and is highly effective 
for enhancing LVdP/dt min (3.2 fold increase when compared to the control; n=16; P<0.001) 
in the presence of high fat. At a concentration of 10 µM, like perhexiline, 50 showed a similar 
trend to increasing LVdP/dt max (1.8 fold increase when compared to the control; n=16 
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P=0.07) and was almost as effective as perhexiline in increasing LVdP/dt min (2.7 fold 
increase when compared to the control; n=16; P<0.01). These results also demonstrate that 
2 µM perhexiline and 10 µM 50 have significant lusitropic effects, a feature that current 
pharmacological treatments for HF lack. It can be noted that the apparent 5-fold loss of 
potency of 50 compared to perhexiline is in accord with the relative potencies vs CPT-1; 
however - as it cannot be assumed that CPT-1 is the only target, or even the major target, or 
that the ratio of potencies for perhexiline and 50 vs other targets will remain the same – the 
importance of this observation cannot be determined.  At present, most drug therapies for 
HF only improve systolic function such as cardiac contractility, and therefore only benefit 
patients with systolic HF.32 As such, perhexiline and 50 show promising potential for use in 
diastolic HF, a condition in which cardiac relaxation is impaired, as opposed to contractility, 
and where there are currently no well-defined existing treatments.32-34 Furthermore, 50 at 2 
µM shows a small improvement on both cardiac parameters with clear evidence of dose 
dependency.  
 
CONCLUSION 
In summary, these results reveal that 4,4-gem-difluoro-perhexiline 50 (FPER-1) holds a 
similar therapeutic profile to perhexiline 1 and thus 50, and possibly other analogues of 
perhexiline, may have the same potential for the treatment of HF and cardiovascular 
diseases, but without the metabolic liability of the parent compound. As a consequence, 
compounds with the properties exemplified by 50 are expected to be suitable for use across 
a broader spectrum of the patient population and not to require additional monitoring of drug 
plasma concentrations or patient phenotyping, both of which limit drug use and convenience.  
However, it is also clear from these studies that elucidation of the mechanism of action of 
perhexiline will be required before it will be possible to conduct an informed drug discovery 
programme to generate a perhexiline-like drug for clinical development. 
 
EXPERIMENTAL SECTION 
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General Methods: All reactions were carried out under a nitrogen or argon atmosphere with 
dry solvents under anhydrous conditions, unless otherwise mentioned. Solvents and 
reagents: anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), methylene chloride 
(CH2Cl2) and toluene were purchased from commercial suppliers. Reagents were purchased 
at the highest commercial quality, used without further purification and handled in 
accordance with COSHH regulations. Chromatography: flash chromatography (FC) was 
carried out on silica gel (Merck Silica gel Si 60, 40-63 µm) according to the method 
described by Still.35 Thin-layer chromatography (TLC) was carried out on glass-based 0.25 
mm Merck silica gel plates (60F-254) which were developed with UV irradiation (254 nm and 
365 nm), an aqueous solution of KMnO4 and an ethanol solution of ammonium molybdate, 
and heat as developing agents. 1H NMR spectra: these were recorded at 400 MHz on a 
Bruker ADVANCEIII 400 instrument. Chemical shifts (δH) are given in parts per million (ppm) 
as referenced to the appropriate residual solvent peak. 13C NMR spectra: these were 
recorded at 101 MHz on a Bruker ADVANCE III 400 instrument. Chemical shifts (δC) are 
given in parts per million (ppm) as referenced to CHCl3. 19F NMR spectra: these were 
recorded at 376 MHz on a Bruker ADVANCE III 400 instrument without 1H decoupling. 
Chemical shifts (δC) are given in parts per million (ppm) as referenced to CFCl3 as 0 ppm. All 
NMR spectra were recorded at 298K unless otherwise stated. The following abbreviations 
were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, m = multiplet, br = broad. Purities of all tested compounds were determined by 
reverse phase HPLC-MS using an Agilent 1200 series chromatograph system coupled with 
an Agilent G6120 signal quadrupole detector equipped with an electrospray ionisation 
source and detection in positive mode. HPLC conditions for purity analysis: Zorbax Eclipse 
Plus C18 column, 4.6 × 100 mm, 3.5 µm; mobile phase: 75% MeOH / 25% H2O with 0.1% 
formic acid; flow rate: 1 mL/min. All tested compounds were found to be at least 96% purity. 
HRMS:  analyses were performed using an LTQ Orbitrap XL MS spectrometer.  
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Representative procedures for carbocyclic perhexiline analogues. 
6-((tert-Butyldimethylsilyl)oxy)hexan-2-one  
A solution of MeLi (14.8 mL, 23.71 mmol, 1.6 M in Et2O) was added at -78 °C to an Et2O (10 
mL) solution of δ-valerolactone (2.158 g, 21.55 mmol). The resulting reaction mixture was 
stirred for 1 h at -78 °C before quenching with NH4Cl (10 mL, sat. aq.) and dilution with 
EtOAc (20 mL). The layers were separated and the organic layer was washed with brine (20 
mL), dried (Na2SO4) and concentrated under reduced pressure to give the crude hydroxy 
ketone, which was used directly without further purification. 
TBSCl (3.92 g, 26.0 mmol) and imidazole (2.31 g, 33.93 mmol) were added at 0 °C to a 
CH2Cl2 (10 mL) solution of the crude hydroxy ketone. The resulting mixture was allowed to 
warm to 23 °C and stirred for 3 h prior to quenching with a saturated solution of NaHCO3 (10 
mL) and dilution with CH2Cl2 (10 mL). The layers were separated, and the aqueous layer 
was extracted with CH2Cl2 (2 × 5 mL). The combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure. FC (silica gel, hexanes:EtOAc 5:1) afforded 6-
((tert-Butyldimethylsilyl)oxy)hexan-2-one (4.64 g, 93% for two steps) as a colourless oil. 1H 
NMR (400 MHz, CDCl3) δ = 3.60 (t, J = 6.3 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.12 (s, 3H), 
1.69 – 1.58 (m, 2H), 1.56 – 1.45 (m, 2H), 0.88 (s, 9H), 0.03 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ = 209.1, 62.8, 43.5, 32.2, 29.8, 25.9, 20.3, 18.3, -5.3. m/z (ESI) 231 [M+H]+. 
 
7-((tert-Butyldimethylsilyl)oxy)-1-cyclohexyl-1-hydroxyheptan-3-one (2a) 
Method A: a solution of freshly prepared LDA (3.80 mL, 3.80 mmol, 1.0 M in THF/hexanes) 
was added at -78 °C to a THF (5 mL) solution of 6-((tert-butyldimethylsilyl)oxy)hexan-2-one 
(730 mg, 3.17 mmol). The resulting mixture was stirred for 1 h at -78 °C before 
cyclohexanecarboxaldehyde (426 mg, 460 µL, 3.80 mmol) was added. The reaction mixture 
was stirred at -78 °C for further 30 min before quenching with NH4Cl (10 mL, sat. aq.) and 
dilution with EtOAc (10 mL). The layers were separated and the organic layer was washed 
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with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. FC (silica gel, 
hexanes:EtOAc 2:1) furnished the aldol adduct 2a (955 mg, 88 %) as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ = 3.85 – 3.73 (m, 1H), 3.60 (t, J = 6.2 Hz, 2H), 3.04 (brs, 1H), 2.67 
– 2.39 (m, 4H), 1.89 – 1.78 (m, 1H), 1.78 – 1.70 (m, 2H), 1.69 – 1.57 (m, 4H), 1.54 – 1.47 
(m, 2H), 1.41 – 1.29 (m, 1H), 1.29 – 1.09 (m, 3H), 1.09 – 0.92 (m, 2H), 0.88 (s, 9H), 0.04 (s, 
6H); 13C NMR (101 MHz, CDCl3) δ = 212.6, 71.7, 62.7, 46.1, 43.4, 43.0, 32.1, 28.8, 28.3, 
26.4, 26.2, 26.1, 25.9, 20.1, 18.3, -5.3. m/z (ESI) 343 [M+H]+. 
 
(E)-7-((tert-Butyldimethylsilyl)oxy)-1-cyclohexylhept-1-en-3-one (3a) 
Method B: Et3N (540 µL, 3.87 mmol) and MsCl (150 µL, 1.94 mmol) were added at 0 °C to a 
CH2Cl2 solution of aldol adduct 2a (440 mg, 1.28 mmol). The solution was stirred for 1 h at 0 
°C followed by addition of DBU (290 µL, 1.94 mmol). The resulting mixture was warmed to 
23 °C and stirred for further 2 h prior to quenching with NH4Cl (10 mL, sat. aq.) and dilution 
with EtOAc (20 mL). The layers were separated and the organic layer was washed with brine 
(20 mL), dried (Na2SO4) and concentrated under reduced pressure. FC (silica gel, 
hexanes:EtOAc 5:1) afforded the enone 3a (410 mg, 98%) as a pale yellow oil. 1H NMR (400 
MHz, CDCl3) δ = 6.76 (dd, J = 16.0, 6.8 Hz, 1H), 6.05 (dd, J = 16.0, 1.4 Hz, 1H), 3.63 (t, J = 
6.2 Hz, 2H), 2.57 (t, J = 7.3 Hz, 2H), 2.19 – 2.08 (m, 1H), 1.81 – 1.73 (m, 4H), 1.73 – 1.60 
(m, 3H), 1.60 – 1.49 (m, 3H), 1.36 – 1.26 (m, 2H), 1.22 – 1.09 (m, 2H), 0.89 (m, 9H), 0.04 
(m, 6H); 13C NMR (101 MHz, CDCl3) δ = 201.1, 152.1, 127.8, 62.9, 40.6, 39.8, 32.3, 31.8, 
25.95, 25.92, 25.7, 20.8, 18.3, -5.3. m/z (ESI) 325 [M+H]+. 
 
7-Cyclohexyl-7-cyclopropyl-5-oxoheptanal (5a) 
Method C:23 a solution of cyclopropylmagnesium bromide (1.67 mL, 1.67 mmol, 1.0 M in 2-
MeTHF) was added at -78 °C to a suspension of CuI (159 mg, 0.835 mmol) in THF (2 mL). 
The resulting mixture was allowed to warm to 0 °C and stirred for further 1 h to give the 
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organocuprate reagent. The solution was then cooled to -78 °C followed by addition of a 
THF solution (0.5 mL) of enone 3a (180 mg, 0.56 mmol) and TMSCl (142 µL, 1.12 mmol). 
The reaction mixture was stirred at -78 °C for 1 h before quenching with a MeOH solution of 
PTSA (2 N, 5 mL, 10 mmol). The solution was stirred at 23 °C for 2 h prior to dilution with 
EtOAc (20 mL). The layers were separated and the organic layer was washed with brine (10 
mL), dried (Na2SO4) and concentrated under reduced pressure. The mixture was passed 
through a plug of silica gel (EtOAc) to give the corresponding alcohol, which was used 
without further purification. 
Dess−Martin periodinane (285 mg, 0.67 mmol) was added at 23 °C to a CH2Cl2 solution (5 
mL) of the alcohol above. The reaction mixture was stirred for 6 h before quenching with 
Na2SO3 (5 mL, sat. aq.). The resulting mixture was extracted with CH2Cl2 (3 × 5 mL), 
combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by FC (silica gel, hexanes:EtOAc 3:1) afforded the dicarbonyl 
compound 5a (101 mg, 73 % for three steps). 1H NMR (400 MHz, CDCl3) δ = 9.82 (t, J = 1.5 
Hz, 1H), 2.59 – 2.39 (m, 5H), 1.78 – 1.42 (m, 8H), 1.42 – 1.26 (m, 1H), 1.26 – 0.91 (m, 6H), 
0.68 – 0.49 (m, 1H), 0.49 – 0.37 (m, 1H), 0.37 – 0.22 (m, 1H), 0.12 (tt, J = 14.5, 7.2 Hz, 1H), 
-0.09 (td, J = 9.3, 5.3 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ = 212.1, 201.3, 46.0, 45.5, 43.4, 
42.8, 32.1, 30.6, 30.1, 26.8, 26.74, 26.68, 19.8, 14.21 5.6, 3.4. m/z (ESI) 251 [M+H]+. 
 
2-(2-Cyclohexyl-2-cyclopropylethyl)piperidine (6a) 
Method D:24 NH4OAc (53 mg, 0.69 mmol), NaBCNH3 (41 mg, 0.65 mmol) and 3 Å molecular 
sieves (100 mg) were added at 23 °C to a MeOH solution (2 mL) of dicarbonyl compound 5a 
(78 mg, 0.31 mmol). The resulting mixture was stirred at 23 °C for 16 h before filtration 
through a pad of Celite®. The filtrate was concentrated under reduced pressure. The residue 
was purified by FC (silica gel, MeOH:CH2Cl2 0:100 → 10:90) to afford compound 6a (58 mg, 
78 %, mixture of diastereoisomers, purity > 97%) as a pale yellow oil.  NMR spectra were 
recorded by using the HCl salt of the compound, which was prepared by treating 6a (10 mg) 
22 
 
with HCl (200 µL, 1.25 M in MeOH) followed by concentration under reduced pressure. 1H 
NMR (400 MHz, CDCl3) δ = 9.24 (brs, 2H), 3.51 – 3.38 (m, 1H), 3.27 (dd, J = 13.1, 7.0 Hz, 
0.5H), 3.21 – 3.07 (m, 0.5H), 2.83 (dtd, J = 15.9, 12.7, 3.2 Hz, 1H), 2.22 – 1.53 (m, 12H), 
1.53 – 0.96 (m, 7H), 0.85 (ddd, J = 16.2, 13.6, 6.8 Hz, 0.5H), 0.72 – 0.37 (m, 7.5H), 0.24 – 
0.07 (m, 3H), 0.29 – 0.08 (m, 1.5H), 0.06 – -0.03 (m, 0.5 H); 13C NMR (101 MHz, CDCl3) δ = 
55.9, 55.6, 44.8, 44.7, 44.5, 44.29, 42.9, 42.0, 36.40, 36.35, 30.9, 30.7, 30.0, 29.0, 28.4, 
27.1, 26.94, 26.87, 26.75, 26.72, 22.5, 22.4, 22.3, 22.2, 13.61, 13.56, 4.9, 4.5, 4.0, 3.7. m/z 
(ESI) 236 [M+H]+; HRMS (ESI) calcd for C16H30N+ [M+H]+ 236.2373, found 236.2369. 
 
Ethyl 4-(methoxymethoxy)cyclohexanecarboxylate (20)  
DIPEA (992 µL, 5.8 mmol) and MOMCl (330 µL, 4.35 mmol) were added to a CH2Cl2 (7 mL) 
solution of ethyl 4-hydroxycyclohexanecarboxylate (500 mg, 2.9 mmol) cooled to 0 °C. After 
stirring at r.t. for 6 h H2O (5 mL) was added, the layers were separated and the organic 
phase was dried (Na2SO4). The solvent was evaporated and the crude was purified by FC 
(hexane:EtOAc 8:2) to give 20 (590 mg, 93% yield) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ = 4.47 (s, 1 H), 3.94 (q, 2 H, J = 7.0 Hz, 2 H), 3.58-3.51 (m, 1H), 3.17 (s, 3 H), 2.23 
– 2.21 (m, 1 H), 1.93-1.78 (m, 2H), 1.76-1.65 (m, 2H), 1.63-1.52 (m, 2H), 1.51-1.41 (m, 3H), 
1.07 (t, J = 7.0 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ = 175.0, 94.5, 74.7, 60.0, 54.9, 42.2, 
29.6, 23.8, 14.0. m/z (ESI) 217 [M+H+] 
 
4-(Methoxymethoxy)cyclohexanecarbaldehyde (21) 
NaOH (210 mg, 5.24 mmol) was added to a solution of 20 (570 mg, 2.62 mmol) in a 
THF:H2O 4:1 mixture (10 mL). The reaction was stirred overnight, then H2O (5 mL) was 
added. The layers were separated, the aqueous phase was acidified with 1N HCl until pH 1 
was reached and then extracted with EtOAc (10 mL). The organic phase was dried 
(Na2SO4), filtered and the solvent was removed under reduced pressure to give the 
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corresponding acid (413 mg ,83% yield) as a white solid. Et3N (250 µL, 1.80 mmol) and ethyl 
chloroformate (172 µL, 1.80 mmol) were added to a dry THF (5 mL) solution of acid (300 
mg, 1.6 mmol) cooled to 0 °C. The resulting suspension was stirred at the same temperature 
for 1h and then filtered through Celite. The filtrate was then added to a solution of NaBH4 
(116 mg, 3.1 mmol) in water (2 mL) cooled to 0 °C. The reaction mixture was stirred at the 
same temperature for 30 min, quenched with H2O (5 ml) and extracted with EtOAc (10 mL). 
The solvent was removed under reduced pressure and the crude was purified by FC (Hex: 
EtOAc 1:1) to give 298 mg of the corresponding alcohol (268 mg , 96% yield) as a colourless 
oil. A solution of (COCl)2 (133 µL, 1.5 mmol) in CH2Cl2 (3 mL) was added dropwise to a 
solution of DMSO (204 µL, 2.87 mmol) in CH2Cl2 (5 mL), cooled to -78 °C. The reaction was 
stirred at the same temperature for 15 min, then a solution of the alcohol above (200 mg, 
1.15 mmol) in CH2Cl2 (5 mL) was added. After stirring for 1 h, Et3N (800 µL, 5.75 mmol) was 
added. After 30 min the reaction was warmed to r.t, quenched with 1N HCl (aq) and 
extracted with EtOAc (10 mL). The solvent was dried (Na2SO4), filtered and concentrated 
under reduced pressure. The crude was purified by FC (hexane:EtOAc 8:2) to give 58 (165 
mg, 83%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 9.51 (s, 1 H), 4.52 (s, 2 H), 3.66-
3.55 (m, 1H), 3.23 (s, 3 H), 2.20 – 2.23 (m, 1 H), 1.98-1.85 (m, 2H), 1.82-1.70 (m, 1H), 1.67-
1.40 (m, 4H), 1.30 – 1.21 (m, 1H); 13C NMR (101 MHz, CDCl3) δ = 204.2, 94.6, 74.6, 71.9, 
55.1, 48.2, 31.1, 23.7, 21.2. m/z (ESI) 173 [M+H+]. 
 
Cyclohexyl(4-(methoxymethoxy)cyclohexyl)methanol (22) 
A small crystal of iodine was added to a suspension of magnesium shavings (63 mg, 2.58 
mmol) in Et2O (2 mL, nitrogen atmosphere). Bromocyclohexane (317 µL, 2.58 mmol) was 
then added slowly (over 5 min), so as to maintain a gentle reflux. The mixture was heated to 
reflux for 30 min. After cooling to r.t, aldehyde 21 (370 mg, 2.15 mmol) in Et2O (2 mL,), was 
slowly added. After stirring at r.t overnight, NH4Cl (5 mL, sat. aq.) was added and the 
reaction was extracted with EtOAc (10 mL). The organic layer was dried (Na2SO4), filtered 
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and concentrated under reduced pressure. The crude was purified by FC (hexane:EtOAc 
7:3) to give 22 (233 mg, 91%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 4.59 (s, 2 H), 
3.77 - 3.69 (m, 1H), 3.28 (s, 3H), 3.10-2.93 (m, 1H), 2.07- 1.92 (m, 1H), 1.88-1.77 (m, 1H), 
1.74-1.73 (m, 3H), 1.62-1.26 (m, 8H), 1.25- 0.87 (m, 8H); 13C NMR (101 MHz, CDCl3) δ = 
94.5, 79.7, 75.9, 71.3, 55.1, 40.2, 39.8, 39.0, 32.4, 30.2, 29.9, 28.0, 26.5, 24.0, 21.8. m/z 
(ESI) 257 [M+H+] 
 
Cyclohexyl(4-(methoxymethoxy)cyclohexyl)methanone (23) 
PCC (846 mg, 2.25 mmol) was added to a solution of 22 (470 mg, 1.87 mmol) in CH2Cl2 (40 
mL). The reaction was stirred overnight, then filtered through Celite. The filtrate was 
concentrated under reduced pressure and purified by FC (hexane:EtOAc 9:1) to give 23 
(395 mg, 83%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 4.56 (s, 2 H), 3.75 - 3.64 
(m, 1H), 3.27 (s, 3H), 2.50-2.35 (m, 2H), 1.84-1.74 (m, 2H), 1.73-1.62 (m, 6H), 1.61-1.35 (m, 
5H), 1.33- 1.05 (m, 5H); 13C NMR (101 MHz, CDCl3) δ = 216.4, 94.6, 71.0, 55.2, 48.7, 48.0, 
29.8, 28.7, 25.8, 25.7, 23.1. m/z (ESI) 277.2 [M+Na+] 
 
4-(1-Cyclohexyl-2-(piperidin-2-yl)ethyl)cyclohexanol (24) 
A solution of nBuLi (680 µL, 1.7 mmol 2.5 M in hexanes) was added dropwise to a stirred 
solution of 2-picoline (168 µL, 1.7 mmol) in THF (4 mL) at -78 °C. The resulting red solution 
was stirred at that temperature for 10 min before being warmed to -10 °C for 20 min, after 
which the mixture was cooled to -78 °C and a THF (2 mL) solution of 23 (395 mg, 1.55 
mmol) was added. The resulting mixture was stirred at that temperature for 30 min before 
SOCl2 was added (186 µL, 2.55 mmol). The milky reaction mixture was warmed to 0 °C for 
30 min prior to quenching with NH4Cl (10 mL, sat. aq.) and dilution with EtOAc (10 mL). The 
layers were separated and the organic layer was washed with brine (20 mL), dried (Na2SO4) 
and concentrated under reduced pressure. FC (hexane:EtOAc 8:2) gave the intermediate 
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unsaturated 2-pyridines (442 mg, 75%) as a yellow oil. To a solution of these 2-pyridines 
(210 mg, 0.63 mmol) in MeOH (7 mL) a catalytic amount of PtO2 was added. The reaction 
was stirred under a hydrogen atmosphere for 24 h, filtered through a Celite® pad and 
concentrated under reduced pressure. The crude was purified by FC (CH2Cl2:MeOH 9:1) to 
give 2-(2-cyclohexyl-2-(4-(methoxymethoxy)cyclohexyl)ethyl)piperidine (180 mg, 84%) as a 
yellow oil.  
TFA (120 µL, 1.55 mmol) was added to a CH2Cl2 (4 mL) solution of 2-(2-cyclohexyl-2-(4-
(methoxymethoxy)cyclohexyl)ethyl)piperidine (175 mg 0.51 mmol). After stirring for 4 h the 
solvent was removed under reduced pressure and the crude dissolved in THF (3 mL). 1N 
aq. NaOH (1.5 mL) was added and the reaction was stirred for 1 h. H2O (5 mL) and EtOAc 
(10 mL) were added and the layers were separated. The organic layer was dried (Na2SO4) 
and concentrated under reduced pressure to give 24 (130 mg, 86%, purity > 96%) as a 
yellow amorphous solid. .1H NMR (400 MHz, CDCl3) δ = 3.93-3.83 (m, 1H), 2.98 (d, J = 12.1 
Hz, 1H), 2.53 (td, J = 9.6 and 2.6 Hz, 1H), 2.39 – 2.27 (m, 1 H), 2.26 – 2.22 (m, 1 H), 1.68-
0.81 (m, 30 H); 13C NMR (101 MHz, CDCl3) δ = 66.2, 57.0, 47.2, 44.5, 39.8, 39.4, 36.4, 33.1, 
32.9, 32.9, 31.9, 29.6, 27.0, 26.8, 26.7, 26.3, 25.2, 24.9, 23.3. m/z (ESI) 294 [M+H+] 
 
In vitro CPT-1 Inhibition Assay:29 
Preparation of Rat Heart Mitochondrial Suspension (MS): All of the steps below were 
performed on ice or at 4 °C. Three male Wistar rats (8 weeks of age) were sacrificed by 
cervical dislocation, hearts were excised, rinsed twice with ice-cold Homogenization Buffer 
(HB: 10 mM Tris-HCl, 250 mM sucrose, 1 mM EDTA, pH 7.4), blotted, weighed, and finely 
minced with scissors for 5 min. Minced hearts were homogenized in 5 volumes of HB (by 
tissue weight) using a Polytron homogenizer. The homogenate was centrifuged for 10 min at 
600 x g, and the supernatant was removed and saved. The pellet was re-suspended in HB, 
homogenized again, spun for 10 min at 600 x g, and the supernatants from the first and 
second homogenizations were combined. The combined supernatant was centrifuged for 10 
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min at 7000 x g, the supernatant was discarded, the pellet was re-suspended in HB to the 
original homogenization volume and centrifuged again for 10 min at 7000 x g. The 
supernatant was discarded and the pellet of washed mitochondria was re-suspended in HB 
to 0.5 volumes relative to original heart weight. Protein content was determined using the 
Bradford protein assay, the solution was diluted with HB to a protein concentration of 10 
mg/mL, and small individual aliquots of this mitochondrial suspension (MS) were shock-
frozen in LN2 and stored at -80 °C. Aliquots of MS were thawed and diluted with HB to 2 
mg/ml protein just prior to use in CPT-1 assays.  
Each reaction (final volume 200 µL, pH 6.8) contained 0.04 mg of MS protein, 25 mM Tris-
HCl, 150 mM sucrose, 1 mM EDTA, 60 mM KCl, 1.2 mg/mL lipid-free BSA, 0.1 mM 4,4'-
dithiodipyridine, 0.4 mM L-carnitine, 0.04 mM palmitoyl CoA and varying concentrations of 
inhibitor. Reactions were performed in a quartz glass microcuvette, and inhibitors were pre-
incubated for 3 min at 37 °C with all assay components except for L-carnitine and palmitoyl 
CoA. Each inhibitor was dried down from a CH2Cl2 stock, redissolved in the assay buffer 
described above, and appropriate serial dilutions were made. A solution of L-carnitine and 
palmitoyl CoA (in water) was added to initiate the enzyme reaction, and the cuvette was 
placed in a spectrophotometer programmed in kinetic mode to read the increase in 
absorbance at 324 nm for 3.5 min. The slopes of the kinetic curves were calculated and 
compared to the mean of positive controls generated in the absence of any inhibitor (defined 
as 100 % activity), to determine the % control activity for each inhibitor concentration. 
Controls and each inhibitor concentration were analyzed with 5 replicates, and mean +/- SD 
were calculated for each point. IC50 estimates and 95% confidence intervals for the malonyl 
CoA-inhibitable component of the CPT activity were determined following subtraction of the 
non-inhibited activity by non-linear regression of inhibition curves using GraphPad Prism 5 
(GraphPad Software Inc), and each value listed in Table 2 represents the mean IC50 value 
and pooled confidence interval from two independent experiments using each inhibitor. 
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Ex vivo Langendorff Model: 
Briefly, C57BL/6 (25 - 30 g) murine hearts were isolated and mounted onto the Langendorff 
perfusion system and retrogradely perfused with a modified Krebs buffer consisting of 1.2 
mM sodium palmitate pre-conjugated to 3% bovine serum albumin (BSA).36 The buffer was 
perfused at a constant pressure of 80 mmHg at 37 °C and continuously gassed with 95% O2 
/ 5% CO2. Following 10 min stabilisation in control (BSA-Palmitate) Krebs buffer, hearts were 
perfused for 30 min with 1) control (BSA-Palmitate), 2) 2 µM perhexiline, 3) 2 µM 50, or 4) 10 
µM 50. The maximal and minimal change in left ventricular pressure over time (LVdP/dt max 
and min, respectively) were calculated from the left ventricular pressure recorded throughout 
the 40 minutes of perfusion. All data are expressed as mean ± SEM and statistical 
comparison between groups were performed using 1-way ANOVA, followed by the post-hoc 
Bonferroni test. Values of P<0.05 were deemed as significant. 
 
Pharmacokinetics assays: 
Routine in vitro stability studies were conducted by Cyprotex Ltd (Macclesfield, UK) and in 
vivo pharmacokinetics were conducted by Sai Life (Pune, India) using standard 
methodology. 
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